Izeltabart (CAS: 2642078-60-0)
Izeltabart is a humanized IgG1κ monoclonal antibody that targets ADAM9, a protein associated with tumor progression. It is used to create antibody-drug conjugates (ADCs) for targeted cancer therapy.
Key Features:
- Target: Specifically binds to ADAM9, found on various tumor cells.
- Mechanism: Helps deliver cytotoxic agents directly to ADAM9-expressing tumor cells through ADCs.
- Therapeutic Use: Investigated for treating cancers like non-small cell lung cancer (NSCLC) and ovarian cancer.
Applications:
- Cancer Research: Help to develop ADCs targeting ADAM9-positive tumors, improving treatment precision and reducing toxicity.
- ADC Development: Conjugates with Maytansinoid-based DM21-C to create the ADC IMGC936. IMGC936 exhibits strong anti-cancer activity by targeting ADAM9-positive cells and showing potent effects in tumor models.
Handling and Storage:
- Storage: Store at -20°C, away from light.
- Precautions: Use protective equipment and ensure proper ventilation during handling.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
